Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 52.26
NAS:ALNY's Cash-to-Debt is ranked lower than
51% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. NAS:ALNY: 52.26 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ALNY' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.29  Med: No Debt Max: No Debt
Current: 52.26
3.29
No Debt
Equity-to-Asset 0.91
NAS:ALNY's Equity-to-Asset is ranked higher than
84% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ALNY: 0.91 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ALNY' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.99  Med: 0.66 Max: 0.92
Current: 0.91
-0.99
0.92
Debt-to-Equity 0.02
NAS:ALNY's Debt-to-Equity is ranked higher than
93% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:ALNY: 0.02 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:ALNY' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.07  Med: 0.09 Max: 0.33
Current: 0.02
-0.07
0.33
Debt-to-EBITDA -0.06
NAS:ALNY's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. NAS:ALNY: -0.06 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:ALNY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.37  Med: -0.21 Max: -0.06
Current: -0.06
-0.37
-0.06
Piotroski F-Score: 4
Altman Z-Score: 34.43
Beneish M-Score: -2.35
WACC vs ROIC
22.29%
-199.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -582.63
NAS:ALNY's Operating Margin % is ranked lower than
70% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. NAS:ALNY: -582.63 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ALNY' s Operating Margin % Range Over the Past 10 Years
Min: -900.33  Med: -146.16 Max: -28.95
Current: -582.63
-900.33
-28.95
Net Margin % -565.20
NAS:ALNY's Net Margin % is ranked lower than
71% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. NAS:ALNY: -565.20 )
Ranked among companies with meaningful Net Margin % only.
NAS:ALNY' s Net Margin % Range Over the Past 10 Years
Min: -869.63  Med: -174.03 Max: -27.3
Current: -565.2
-869.63
-27.3
ROE % -40.16
NAS:ALNY's ROE % is ranked lower than
51% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. NAS:ALNY: -40.16 )
Ranked among companies with meaningful ROE % only.
NAS:ALNY' s ROE % Range Over the Past 10 Years
Min: -84.12  Med: -37.04 Max: -13.08
Current: -40.16
-84.12
-13.08
ROA % -33.45
NAS:ALNY's ROA % is ranked lower than
51% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. NAS:ALNY: -33.45 )
Ranked among companies with meaningful ROA % only.
NAS:ALNY' s ROA % Range Over the Past 10 Years
Min: -48.05  Med: -24.36 Max: -5.01
Current: -33.45
-48.05
-5.01
ROC (Joel Greenblatt) % -328.56
NAS:ALNY's ROC (Joel Greenblatt) % is ranked higher than
53% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. NAS:ALNY: -328.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ALNY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2120.98  Med: -353.24 Max: -149.42
Current: -328.56
-2120.98
-149.42
3-Year Revenue Growth Rate 13.40
NAS:ALNY's 3-Year Revenue Growth Rate is ranked higher than
66% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. NAS:ALNY: 13.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ALNY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -5.9 Max: 108
Current: 13.4
0
108
3-Year EBITDA Growth Rate -0.50
NAS:ALNY's 3-Year EBITDA Growth Rate is ranked lower than
56% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. NAS:ALNY: -0.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ALNY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -65.3  Med: -0.5 Max: 62.2
Current: -0.5
-65.3
62.2
3-Year EPS without NRI Growth Rate -3.80
NAS:ALNY's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NAS:ALNY: -3.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ALNY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.8  Med: -3.8 Max: 66.7
Current: -3.8
-52.8
66.7
GuruFocus has detected 2 Warning Signs with Alnylam Pharmaceuticals Inc NAS:ALNY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ALNY's 30-Y Financials

Financials (Next Earnings Date: 2018-08-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

ALNY Guru Trades in Q2 2017

Joel Greenblatt 9,684 sh (New)
George Soros 7,000 sh (New)
Steven Cohen 50,000 sh (New)
Pioneer Investments 147,194 sh (+68.69%)
Jim Simons Sold Out
Dodge & Cox 9,185,820 sh (-2.27%)
Vanguard Health Care Fund 8,047,957 sh (-5.86%)
John Griffin 1,376,700 sh (-13.42%)
» More
Q3 2017

ALNY Guru Trades in Q3 2017

Steven Cohen 85,000 sh (+70.00%)
John Griffin 1,531,899 sh (+11.27%)
Steven Cohen 150,000 sh (unchged)
Steven Cohen 100,000 sh (unchged)
George Soros Sold Out
Dodge & Cox 9,141,495 sh (-0.48%)
Vanguard Health Care Fund 7,945,504 sh (-1.27%)
Pioneer Investments 95,572 sh (-35.07%)
Joel Greenblatt 2,499 sh (-74.19%)
» More
Q4 2017

ALNY Guru Trades in Q4 2017

Jim Simons 8,100 sh (New)
Pioneer Investments 129,902 sh (+35.92%)
Steven Cohen 88,886 sh (+4.57%)
Joel Greenblatt Sold Out
Dodge & Cox 8,231,595 sh (-9.95%)
John Griffin 1,338,300 sh (-12.64%)
Vanguard Health Care Fund 6,670,468 sh (-16.05%)
» More
Q1 2018

ALNY Guru Trades in Q1 2018

Jim Simons 235,400 sh (+2806.17%)
Steven Cohen 908,046 sh (+921.58%)
Vanguard Health Care Fund 6,889,417 sh (+3.28%)
John Griffin Sold Out
Pioneer Investments 102,902 sh (-20.78%)
Dodge & Cox 4,692,841 sh (-42.99%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-03-31 Add 3.28%0.06%$115.92 - $148.54 $ 104.62-19%6,889,417
Dodge & Cox 2018-03-31 Reduce -42.99%0.35%$115.92 - $148.54 $ 104.62-19%4,692,841
Dodge & Cox 2017-12-31 Reduce -9.95%0.09%$114.49 - $139.98 $ 104.62-17%8,231,595
Dodge & Cox 2017-12-31 Reduce -9.95%0.09%Premium Member Access $127.05 $ 104.62-18%8,231,595
Vanguard Health Care Fund 2017-12-31 Reduce -16.05%0.32%$114.49 - $139.98 $ 104.62-17%6,670,468
Joel Greenblatt 2017-12-31 Sold Out $114.49 - $139.98 $ 104.62-17%0
Dodge & Cox 2017-09-30 Reduce -0.48%$72.53 - $118.27 $ 104.6223%9,141,495
Vanguard Health Care Fund 2017-09-30 Reduce -1.27%0.02%$72.53 - $118.27 $ 104.6223%7,945,504
Joel Greenblatt 2017-09-30 Reduce -74.19%0.01%$72.53 - $118.27 $ 104.6223%2,499
George Soros 2017-09-30 Sold Out 0.01%$72.53 - $118.27 $ 104.6223%0
Dodge & Cox 2017-06-30 Reduce -2.27%0.01%$47.75 - $85.21 $ 104.6265%9,185,820
Vanguard Health Care Fund 2017-06-30 Reduce -5.86%0.06%$47.75 - $85.21 $ 104.6265%8,047,957
Joel Greenblatt 2017-06-30 New Buy0.01%$47.75 - $85.21 $ 104.6265%9,684
George Soros 2017-06-30 New Buy0.01%$47.75 - $85.21 $ 104.6265%7,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Alnylam Pharmaceuticals Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BGNE, NAS:JUNO, NAS:JAZZ, NAS:BLUE, NAS:SGEN, HKSE:02269, NAS:BIVV, NAS:AVXS, NAS:NBIX, NAS:ALKS, OCSE:GEN, NAS:SAGE, NAS:EXEL, NAS:INCY, BOM:532523, HKSE:01548, NAS:TECH, OSTO:SOBI, NAS:IONS, HKSE:01530 » details
Traded in other countries:DUL.Germany,
Headquarter Location:USA
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. Alnylam has partnered several pipeline candidates, including amyloidosis drug patisiran, hemophilia drug fitusiran, and cholesterol drug inclisiran. Up-front fees from research partnerships with firms such as Sanofi, Takeda, Roche, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see milestones and royalties from drugs commercialized under these agreements.

Top Ranked Articles about Alnylam Pharmaceuticals Inc

Dodge & Cox Trims NetApp, Walmart, Target Firm's largest sales of the 1st quarter
Dodge & Cox, the investment firm founded by Van Duyn Dodge and E. Morris Cox, sold shares of the following stocks in the first quarter. Read more...
Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH)
Vanguard Health Care Fund's Largest Sales of the 4th Quarter The fund trimmed its UnitedHealth, Cigna, Eli Lilly holdings
The Vanguard Health Care Fund (Trades, Portfolio), which is managed by Jean Hynes, sold shares of the following stocks in the fourth quarter. Read more...
A Look at Alnylam Pharmaceuticals' Rolling NDA What the rolling NDA submission process looks like for patisiran
At the end of last week, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced it had initiated a rolling submission for a new drug application (NDA) rooted in an asset called patisiran. This is a drug that analysts expect could top out at more than $1 billion in annual sales for Alnylam if it is successful in garnering a regulatory greenlight from the U.S. Food and Drug Administration (FDA) and, as such, it is one that markets are keeping an eye on as strongly indicative of wider investor sentiment surrounding the company and its long-term prospects right now. Read more...
Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran
Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)
Analysts Act on Health Care Stocks Leerink upgrades AbbVie to Outperform
Analysts have taken action on some health care stocks. Read more...
Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

Ratios

vs
industry
vs
history
PB Ratio 5.98
ALNY's PB Ratio is ranked lower than
68% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ALNY: 5.98 )
Ranked among companies with meaningful PB Ratio only.
ALNY' s PB Ratio Range Over the Past 10 Years
Min: 2.07  Med: 5.1 Max: 21.37
Current: 5.98
2.07
21.37
PS Ratio 106.74
ALNY's PS Ratio is ranked lower than
87% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALNY: 106.74 )
Ranked among companies with meaningful PS Ratio only.
ALNY' s PS Ratio Range Over the Past 10 Years
Min: 3.1  Med: 24.28 Max: 222.78
Current: 106.74
3.1
222.78
EV-to-EBIT -16.62
ALNY's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. ALNY: -16.62 )
Ranked among companies with meaningful EV-to-EBIT only.
ALNY' s EV-to-EBIT Range Over the Past 10 Years
Min: -94.6  Med: -12.7 Max: -1.3
Current: -16.62
-94.6
-1.3
EV-to-EBITDA -17.04
ALNY's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. ALNY: -17.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -207.5  Med: -13.8 Max: -1.4
Current: -17.04
-207.5
-1.4
EV-to-Revenue 96.68
ALNY's EV-to-Revenue is ranked lower than
82% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. ALNY: 96.68 )
Ranked among companies with meaningful EV-to-Revenue only.
ALNY' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.7  Med: 18.8 Max: 200.5
Current: 96.68
0.7
200.5
Current Ratio 14.61
ALNY's Current Ratio is ranked higher than
86% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. ALNY: 14.61 )
Ranked among companies with meaningful Current Ratio only.
ALNY' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 5.29 Max: 18.24
Current: 14.61
1.88
18.24
Quick Ratio 14.61
ALNY's Quick Ratio is ranked higher than
86% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. ALNY: 14.61 )
Ranked among companies with meaningful Quick Ratio only.
ALNY' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 5.29 Max: 18.24
Current: 14.61
1.88
18.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.90
ALNY's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ALNY: -8.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -331.8  Med: -14.6 Max: -1
Current: -8.9
-331.8
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 7.49
ALNY's Price-to-Net-Cash is ranked lower than
51% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. ALNY: 7.49 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ALNY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.7  Med: 9.4 Max: 92.77
Current: 7.49
3.7
92.77
Price-to-Net-Current-Asset-Value 6.91
ALNY's Price-to-Net-Current-Asset-Value is ranked lower than
54% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. ALNY: 6.91 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALNY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.54  Med: 9.18 Max: 82.06
Current: 6.91
3.54
82.06
Price-to-Tangible-Book 5.97
ALNY's Price-to-Tangible-Book is ranked lower than
59% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. ALNY: 5.97 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALNY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.2  Med: 5.07 Max: 15.16
Current: 5.97
2.2
15.16
Price-to-Median-PS-Value 4.40
ALNY's Price-to-Median-PS-Value is ranked lower than
95% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. ALNY: 4.40 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALNY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 1.06 Max: 7.93
Current: 4.4
0.14
7.93
Earnings Yield (Greenblatt) % -6.03
ALNY's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. ALNY: -6.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALNY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -79.2  Med: -7.85 Max: -1.1
Current: -6.03
-79.2
-1.1

More Statistics

Revenue (TTM) (Mil) $92.85
EPS (TTM) $ -5.58
Beta3.26
Volatility50.20%
52-Week Range $70.76 - 153.99
Shares Outstanding (Mil)100.52

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 126 289 406
EBIT (Mil $) -750 -716 -780
EBITDA (Mil $) -729 -686 -733
EPS ($) -7.84 -6.96 -7.35
EPS without NRI ($) -7.84 -6.96 -7.35
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}